Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01449461
Title A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Ariad Pharmaceuticals
Indications

Advanced Solid Tumor

diffuse large B-cell lymphoma

lung non-small cell carcinoma

anaplastic large cell lymphoma

Therapies

Brigatinib

Age Groups: senior | adult
Covered Countries

Additional content available in CKB BOOST